LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Nektar Therapeutics

Uždarymo kaina

0.66 -1.49

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

0.65

Max

0.68

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-58M

-51M

Pardavimai

-19M

10M

Pelnas, tenkantis vienai akcijai

-0.24

Pelno marža

-486.444

Darbuotojai

61

EBITDA

-58M

-41M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+661.19% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-07

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

15M

148M

Ankstesnė atidarymo kaina

2.15

Ankstesnė uždarymo kaina

0.66

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

Nektar Therapeutics Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-06-06 14:31; UTC

Uždarbis

New York State Retirement Fund Posts 5.84% Annual Investment Return

2025-06-06 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-06-06 20:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-06-06 20:33; UTC

Uždarbis

These Stocks Moved the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

2025-06-06 19:36; UTC

Rinkos pokalbiai

Oil Futures Post Solid Weekly Gains -- Market Talk

2025-06-06 19:28; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Rise on Demand Expectations -- Market Talk

2025-06-06 18:46; UTC

Rinkos pokalbiai

Gold Faced With Tariff Uncertainty Offset by ETF Withdrawals -- Market Talk

2025-06-06 18:02; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Continues to Decline -- Market Talk

2025-06-06 16:35; UTC

Uždarbis

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

2025-06-06 16:34; UTC

Uždarbis

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

2025-06-06 16:21; UTC

Rinkos pokalbiai

Canadian Unemployment Set to Continue Feel Trade War Pressures -- Market Talk

2025-06-06 16:20; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-06-06 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-06-06 16:20; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2025-06-06 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-06-06 16:07; UTC

Rinkos pokalbiai

Market Talk Roundup: Latest on U.S. Politics

2025-06-06 16:07; UTC

Rinkos pokalbiai

Base Metal Prices Slide But Copper Set to End Week Higher -- Market Talk

2025-06-06 15:53; UTC

Rinkos pokalbiai

Mexican Inflation Seen Rising in May -- Market Talk

2025-06-06 15:36; UTC

Rinkos pokalbiai

Dollar's Boost From U.S. Jobs Data Could Be Limited -- Market Talk

2025-06-06 15:36; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-06-06 15:33; UTC

Rinkos pokalbiai

Gold Futures Slide After Jobs Data Surprises to Upside -- Market Talk

2025-06-06 15:16; UTC

Rinkos pokalbiai

Tesla Showing Signs of Weakness in Key Regions -- Market Talk

2025-06-06 15:05; UTC

Rinkos pokalbiai

Silver at its Highest In Nearly 15 Years -- Market Talk

2025-06-06 14:35; UTC

Rinkos pokalbiai

Weakening Canadian Job Market Seen Keeping BoC in Easing Mode -- Market Talk

2025-06-06 14:28; UTC

Rinkos pokalbiai

Bitcoin Rises After Above-Forecast U.S. Jobs Data -- Market Talk

2025-06-06 14:28; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-06-06 14:28; UTC

Rinkos pokalbiai

Canada's Job Market Weakens But Not Seen Collapsing -- Market Talk

2025-06-06 14:15; UTC

Rinkos pokalbiai

Oil Rises on U.S.-China Talks Optimism -- Market Talk

2025-06-06 14:12; UTC

Uždarbis

Palantir and Super Micro Computer Stocks Rise as Broadcom Posts Strong AI Revenue -- Barrons.com

2025-06-06 14:09; UTC

Uždarbis

Broadcom, the $1 Trillion Stock You Shouldn't Ignore, Makes AI Investment Case -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Nektar Therapeutics Prognozė

Kainos tikslas

By TipRanks

661.19% į viršų

12 mėnesių prognozė

Vidutinis 5.1 USD  661.19%

Aukščiausias 7 USD

Žemiausias 2 USD

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Nektar Therapeutics kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

6 ratings

5

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

0.5949 / 0.7406Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Strong Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. The company serves its clients in the United States and internationally. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.